AVEO garners $100M from stock offering

AVEO Pharmaceuticals says it will net slightly more than $100 million on its sale of 5.75 million discounted shares, much of which will be used for its ambitious R&D plans. The developer recently grabbed an impressive $125 million upfront from its partnership with Astellas on tivozanib, a promising experimental cancer drug. Story